Learnings from the TOPIC study on the timing of platelet inhibition after ACS
What’s the best choice for ACS patients on DAPT when faced with switching out from the newer, more potent P2Y12 inhibitors to one of the older agents? Do we follow the guidelines or has this new Breaking Trial released during Join EuroPCR opened the door to other considerations? Join R. Mehran as she speaks with the lead author T. Cuisset about a study in an area which, until today, was “data poor”. Learn about results concerning outcomes, bleedings and much more here.